Literature DB >> 26648051

Expression of CD30 as a biomarker to predict response to brentuximab vedotin.

Mina L Xu1, Carlos Acevedo-Gadea2, Stuart Seropian2, Samuel G Katz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26648051      PMCID： PMC7064871          DOI： 10.1111/his.12914

Source DB:  PubMed          Journal:  Histopathology        ISSN： 0309-0167            Impact factor:   5.087


× No keyword cloud information.
  5 in total

1.  Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels.

Authors:  Céline Bossard; Maria Pamela Dobay; Marie Parrens; Laurence Lamant; Edoardo Missiaglia; Corinne Haioun; Antoine Martin; Bettina Fabiani; Richard Delarue; Olivier Tournilhac; Mauro Delorenzi; Philippe Gaulard; Laurence de Leval
Journal:  Blood       Date:  2014-09-15       Impact factor: 22.113

2.  Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells.

Authors:  U Schwab; H Stein; J Gerdes; H Lemke; H Kirchner; M Schaadt; V Diehl
Journal:  Nature       Date:  1982-09-02       Impact factor: 49.962

3.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.

Authors:  Anas Younes; Ajay K Gopal; Scott E Smith; Stephen M Ansell; Joseph D Rosenblatt; Kerry J Savage; Radhakrishnan Ramchandren; Nancy L Bartlett; Bruce D Cheson; Sven de Vos; Andres Forero-Torres; Craig H Moskowitz; Joseph M Connors; Andreas Engert; Emily K Larsen; Dana A Kennedy; Eric L Sievers; Robert Chen
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

4.  Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.

Authors:  Youn H Kim; Mahkam Tavallaee; Uma Sundram; Katrin A Salva; Gary S Wood; Shufeng Li; Sima Rozati; Seema Nagpal; Michael Krathen; Sunil Reddy; Richard T Hoppe; Annie Nguyen-Lin; Wen-Kai Weng; Randall Armstrong; Melissa Pulitzer; Ranjana H Advani; Steven M Horwitz
Journal:  J Clin Oncol       Date:  2015-07-20       Impact factor: 44.544

5.  Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.

Authors:  Eric D Jacobsen; Jeff P Sharman; Yasuhiro Oki; Ranjana H Advani; Jane N Winter; Celeste M Bello; Gary Spitzer; Maria Corinna Palanca-Wessels; Dana A Kennedy; Pamela Levine; Jing Yang; Nancy L Bartlett
Journal:  Blood       Date:  2015-01-08       Impact factor: 22.113
  5 in total
  2 in total

1.  Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Minimum Age Working Group.

Authors:  Lia Gore; S Percy Ivy; Frank M Balis; Eric Rubin; Katherine Thornton; Martha Donoghue; Samantha Roberts; Suanna Bruinooge; Jennifer Ersek; Nancy Goodman; Caroline Schenkel; Gregory Reaman
Journal:  J Clin Oncol       Date:  2017-10-02       Impact factor: 44.544

Review 2.  Tumor Microenvironment of Lymphomas and Plasma Cell Neoplasms: Broad Overview and Impact on Evaluation for Immune Based Therapies.

Authors:  Sudhir Perincheri
Journal:  Front Oncol       Date:  2021-12-08       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.